On 23rd April, Lukang Pharma's self-developed Class II new veterinary drug for pets, Firocoxib and its chewable tablets were approved by the Ministry of Agriculture and issued a new drug certificate, making Lukang Pharma the first enterprise in China to approve the registration of this product.

Firocoxib is a non-steroidal anti-inflammatory drug, whose mechanism of action is to exert antipyretic, analgesic and anti-inflammatory effects through selective inhibition of cyclooxygenase-2 (COX-2)-mediated prostaglandin synthesis. It is used to relieve pain and inflammation associated with osteoarthritis, orthopaedic or soft tissue surgery in dogs.

The approval of the new veterinary drug Firocoxib and its chewable tablets further enriched the Company's product range and enhanced its market competitiveness.